YM BioSciences
14
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
35.7%
5 terminated/withdrawn out of 14 trials
64.3%
-22.2% vs industry average
7%
1 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer
Role: lead
Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers
Role: collaborator
Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma
Role: lead
A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases
Role: lead
A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer
Role: lead
Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer
Role: lead
Study Evaluating Inhaled AeroLEF Delivered in 4 Aerosol Delivery Devices in Healthy Volunteers
Role: lead
Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
Role: lead
Phase II Study of Inhaled AeroLEF for Analgesia After ACL Knee Surgery
Role: lead
Study of Single and Multiple Doses of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Healthy Subjects
Role: lead
Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects
Role: lead
Study to Determine Efficacy and Safety of Inhaled AeroLEF in the Treatment of Acute Post-op Pain in Adult Patients Undergoing Elective Orthopedic Surgery
Role: lead
DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer
Role: lead
Phase I Study of Nimotuzumab in Solid Tumours
Role: lead
All 14 trials loaded